2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.